Radar Therapeutics

Radar Therapeutics is presenting at BioCentury Inc. Grand Rounds in Nashville September 9-11! BioCentury Grand Rounds will provide an interdisciplinary forum of top academic, investor, biotech and pharma R&D leaders that will showcase groundbreaking research, clinical insights and transformative technologies with significant commercial potential.

Join BioCentury Inc. this Friday for another installment of Drug Development Disco with our guests Radar Therapeutics CEO Sophia Lugo and Matt Krebs, Growth Team Manager at BioCentury. #biotech #biotechnology https://lnkd.in/e_fSANMv

Join Radar Therapeutics at RNA Leaders in San Diego Sept 4-5! On Day 1 of the conference, CEO Sophia Lugo will be speaking on the Keynote Panel: Scaling RNA Therapies To Deliver On The Promise Of Precision Medicine. The panel will also feature leaders from BioNTech SE, Replicate Bioscience, Inc., Codexis, Inc., Sensible Biotechnologies, and Nutcracker Therapeutics. On Day 2 of the conference, Sophia will be presenting Radar's technology in the presentation: Creating In Vivo, Precisely Expressed mRNA Therapeutics Leveraging ADAR-editing.

Earlier this week, CEO Sophia Lugo had the opportunity to speak on a panel at the Science & Technology Law Institute and GeneOnline international event 'Unlocking the Potential of Nucleic Acid Drugs, from Market Opportunities to Regulatory.' She shared her thoughts on trends in the nucleic acid therapy market, regulatory challenges, and suggestions for APAC and Taiwan policy makers. Nucleic acid therapies offer revolutionary possibilities for disease treatment. This event featured global biopharma experts who shared insights on drug development trends and the current regulatory landscape across various countries with the goal of accelerating nucleic acid drug development.

The DNA/RNA revolution in medicine is advancing rapidly, with genetic medicines allowing patients' cells to serve as their own drug factories. In our latest publication in Cell & Gene (also on Advancing RNA), we delve into the significance of in vivo genetic medicines for complex diseases and the critical need for precise reprogramming of only misbehaving cells. 🎯 Eerik Kaseniit and I explore the challenges faced by current technologies and introduce the RADAR platform for conditionally activated mRNAs as a groundbreaking solution for highly precise, programmable, safe genetic medicines. Thank you, Erin Harris, for this opportunity! Check it out here: https://lnkd.in/gHnEVuqf #DNA #mRNA #synbio

Radar Therapeutics CEO Sophia Lugo will be speaking at the RNA Leaders USA conference September 4-5 in San Diego!   RNA Leaders is a therapeutic conference focusing on the development of mRNA, RNAi, ASOs, oligonucleotides, vaccines, microRNAs, genome editing, wider nucleic acids & RNA targets. If you are interested in learning more about Radar's technology, we invite you to attend Sophia's presentation: Leveraging ADAR Editing To Create Targeted mRNA Therapeutics.

Radar Therapeutics CEO Sophia Lugo will be speaking at the 4th annual mRNA-Based Therapeutics Summit on July 30 in Boston! Sophia will be speaking on the CXOs’ Panel Discussion: Unlocking the Next Frontiers of mRNA-Based Vaccines & Therapeutics to Ensure Better Drugs Reach Patients Faster. The panel will also feature Gritstone bio, Replicate Bioscience, Inc., CureVac, Innovac Therapeutics, and Sail Biomedicines!

Radar Therapeutics is #hiring a Senior Scientist, Bioinformatics in Berkeley, CA. We are looking for a scientist with experience in RNA structure prediction to join our VC-backed startup and work on the development of next-generation gene and cell therapies.

💰 Biotech's Top Investments This Week! 🚀 🇬🇧 🇺🇸 Bicycle Therapeutics | $555 million PIPE | precision medicine | phase 3 in urothelial cancer 🇺🇸 CARGO Therapeutics | $110 million PIPE | cancer cell therapies | phase 2 in cancer 🇩🇰 Adcendo | €98 million ($106.3 million) series A | antibody-drug conjugates (ADC) | lead asset for soft tissue sarcoma 🇬🇧 Grey Wolf Therapeutics | $50 million series B | antigen modulation therapies | phase 1/2 in solid tumors 🇨🇭 SixPeaks Bio | $30 million series A | weight loss therapies 🇺🇸 Genelux | $27.5 million financing | immuno-oncology | phase 3 in ovarian cancer 🇺🇸 Radar Therapeutics | $13.4 million seed | smart programmable medicines | preclinical in undisclosed targets 🇩🇪 Captain T Cell | €8.5 million ($9.2 million) seed | T cell therapies | preclinical Subscribe to our newsletter for more fundraising updates! 🔗 https://lnkd.in/dsgz62YY #fundraising #funding #biotech #venturecapital #fundinground #biotechstartup #seriesa #seriesb #seriesc #investors #IPO #seedfunding

Radar Therapeutics CEO Sophia Lugo will be attending #BIO2024 in San Diego next week! If you're curious about Radar's programmable, precisely expressed genetic medicines, find us on the BIO One-on-One Partnering platform, or reach out to Sophia Lugo via LinkedIn directly.